Abstract 277P
Background
Cetuximab in combination with platinum and 5-fluorouracil is the standard of care in the first-line treatment of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, this seems too toxic for patients with frailty. Our study evaluated the efficacy and safety of tegafur/uracil (UFUR) associated with platinum and cetuximab (UPEx) in frail patients with R/M HNSCC.
Methods
Our study recruited frail patients who were aged > 70 years or performance status (PS) >2. Patients with a histologically confirmed R/M HNSCC unsuitable for locoregional curative therapy were treated with UPEx. The doses of UPEx were Tegafur 200mg twice per day for 14 days, cisplatin 30mg/m(2) at day 1 and cetuximab 500mg/m(2) at day 1, repeated every 2 weeks until progression or unacceptable toxicity. For patients with unfit renal function, carboplatin AUC =2 was used instead of cisplatin. The objective response rate (ORR), overall survival (OS) and progression-free survival (PFS) was estimated.
Results
Forty-two patients were enrolled, including 81% aged > 70 years and 19% PS >2. The primary tumor mainly located in hypopharynx (43%) and oral cavity (43%), followed by oropharynx (10%) and larynx (4%). The ORR was 67%. Median OS and PFS were, respectively, 9.7 months (95% CI 7.4-11.9) and 5.8 months (95% CI 5.1-6.5). No patients had grade 3/4 adverse effects leading to discontinue treatment in our study.
Conclusions
The UPEx regimen was effective and tolerable as first-line treatment in frail patients with R/M HNSCC.
Clinical trial identification
Editorial acknowledgement
The authors thank the heda and neck cancer working group at E-Da hospital for their great assistance of data reviewing and examining.
Legal entity responsible for the study
Meng-che Hsieh.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
420TiP - UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Presenter: Satoru Miura
Session: e-Poster Display Session
443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Presenter: Nathalie Gaspar
Session: e-Poster Display Session
7P - Machine learning intratumoral and axillary lymph node magnetic resonance imaging radiomics for predicting axillary lymph node metastasis in patients with early-stage invasive breast cancer (RBC-01 Study)
Presenter: Yujie Tan
Session: e-Poster Display Session
8P - Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients
Presenter: Shah Zeb Khan
Session: e-Poster Display Session
9P - Survival status of elderly women with HR+ early breast cancer: An analysis of SEER database
Presenter: Wang Hao
Session: e-Poster Display Session
10P - Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials
Presenter: Jessa Gilda Pandy
Session: e-Poster Display Session
11P - Genetically predicted bipolar disorder is causally associated with increased risk of breast cancer: A Mendelian randomization analysis
Presenter: Haoxin Peng
Session: e-Poster Display Session
12P - Stromal tumour-infiltrating lymphocytes in human epidermal growth factor receptor 2-overexpressing breast cancer: Association with negative nodal metastasis
Presenter: Ren Xiaoqiu
Session: e-Poster Display Session
13P - A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
Presenter: Johan Chan
Session: e-Poster Display Session